First contract for a clinical version of our Virtual Tumour model (“Virtual Tumour Clinical”) with Global Pharmaceutical Company, Merck (Merck Serono)
Physiomics plc is pleased to announce that it has signed its first contract for developing Virtual Tumour Clinical with a global pharmaceutical company. The client is Merck Serono, the biopharmaceutical division of Merck, Germany. Revenue from the contract will fall in the 2014/2015 and 2015/2016 financial years and is in the region of the total value of all of Physiomics 2013/2014 sales. As such it clearly represents a step change for Physiomics. The contract runs for 14 months and involves Physiomics scientists working closely with Merck Serono scientists to develop and calibrate a model that can predict optimal combination partners for both marketed and pipeline drugs. The parties will focus on making predictions of clinical outcomes for different dosing and scheduling regimens which, if convincing, could have an impact on final clinical trial design of investigational products, and potential drug combinations. In addition, the parties will look at whether the results can be used to suggest new cancer indications for drug combinations of interest.